On its third-quarter 2026 earnings call, held on Nov. 2, 2026, Tactile Systems (NASDAQ:TCMD) raised its full-year adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $50 million to $52 million. Expanding margins and double-digit growth in lymphedema treatments are offsetting temporary inventory delays in the airway clearance business. Three things management said stand out for long-term investors. Tactile Systems expanded its sales force reach and increased clinic visits by 19% year over year, driving consistent volume growth across medical provider accounts. Expanding patient access and stabilizing Medicare reimbursement have created a reliable revenue engine that funds investments across the portfolio. The business is streamlining how orders move from clinician referral to patient delivery by deploying artificial intelligence order management systems. Management also appointed Steve Kiewiet as Chief Operating Officer to unite patient services, order operations, and revenue cycle management. Together, those moves create capacity for higher referral volumes.
CryptoAlerta — análise de criptomoedas e mercado em tempo real